Viral suppression is the population-level outcome that appears only after several steps in HIV care have worked: people need to know their status, reach antiretroviral therapy (ART), remain in care, and achieve a sufficiently low viral load. The World Health Organization country series used here retains the latest observation for 123 countries and areas. Only 94 of those observations are actually dated 2025. Within that same-year group, the median is 70.0% and the simple unweighted country mean is 66.0%.
The denominator matters. This WHO indicator asks what percentage of all people living with HIV have suppressed viral loads. It is therefore different from the third 95, which asks what percentage of people receiving ART have achieved viral suppression. Countries can have excellent suppression among treated patients while still recording a lower population-level result if people remain undiagnosed or have not yet been linked to treatment.
Table of Contents
This is population-level viral suppression, not the third 95 denominator
WHO describes the HIV treatment cascade as three linked targets. The first 95 asks whether people living with HIV know their status. The second asks whether people who know their positive status are receiving ART. The third asks whether people on ART have a suppressed viral load. Those definitions are summarized in WHO’s HIV data and statistics resources.
The country series in this article uses a broader denominator: all people living with HIV. If every step reached 95%, multiplying 0.95 by 0.95 by 0.95 yields about 85.7%. That is why the WHO global health sector strategy for 2022–2030 expresses the population-level viral-suppression milestone as roughly 86%, rather than 95%. The two percentages describe different positions in the cascade.
This distinction prevents a common error. A country value of 70% does not mean that 30% of treated patients experienced virological failure. The gap can arise before treatment, between diagnosis and treatment initiation, during retention in care, or at the viral-suppression stage itself. The indicator is best read as a combined outcome of the national treatment cascade.
The 2025 median across 94 countries is 70%
Because the latest-country table mixes observation years from 2017 through 2025, the same-year statistics are restricted to the 94 records whose year field is 2025. Their median is 70.0%, the unweighted mean is 65.97%, the first quartile is 52%, and the third quartile is 78%. Half of the countries in this 2025 subset therefore sit between roughly 52% and 78%.
The distribution makes the remaining gap easier to see than a single average. Six countries are below 40%, 23 are between 40% and 59%, 30 are between 60% and 74%, 24 are between 75% and 85%, and 11 are at or above 86%. In other words, the largest group is still below three quarters of all people living with HIV having suppressed viral loads.
Botswana, Saudi Arabia and Lesotho lead the 2025 observations
Botswana has the highest retained 2025 value at 97%, followed by Saudi Arabia at 96% and Lesotho at 95%. Cambodia, Eswatini and Zambia each report 93%; Namibia and Rwanda are at 92%; Zimbabwe is at 91%; and Kenya reaches 87%. Malawi is exactly 86%. Several countries in eastern and southern Africa therefore appear near or above the population-level cascade milestone in this same-year subset.
| Rank | Country | 2025 viral suppression |
|---|---|---|
| 1 | Botswana | 97% |
| 2 | Saudi Arabia | 96% |
| 3 | Lesotho | 95% |
| 4 | Cambodia | 93% |
| 4 | Eswatini | 93% |
| 4 | Zambia | 93% |
| 7 | Namibia | 92% |
| 7 | Rwanda | 92% |
| 9 | Zimbabwe | 91% |
| 10 | Kenya | 87% |
A high value should not be mistaken for low HIV prevalence. Some countries with a substantial HIV burden can also have strong treatment-cascade outcomes. This metric describes the share of people already living with HIV who reach viral suppression; it does not measure how many people in the total population have HIV, nor how many new infections occurred during the year.
Low values point to gaps somewhere across the full care cascade
At the lower end of the 2025 subset, Afghanistan is at 12%, Djibouti 25%, Mauritius 27%, Tunisia 29%, Yemen 30%, and Egypt 38%. Bangladesh, Belize, Comoros and the Philippines are each at 40%. These observations identify a large population-level suppression gap, but they do not identify the cause of that gap on their own.
Possible bottlenecks can occur at testing and diagnosis, linkage to care, ART initiation, treatment retention, access to routine viral-load monitoring, or the final suppression stage. The country indicator cannot separate those mechanisms without additional data. It is therefore more defensible to use the map as a screening view of where outcomes differ and then consult country-specific programme evidence before attributing a cause.
South Africa is at 77%, India 74% and Brazil 69% in 2025
Among large countries with 2025 observations, South Africa records 77%, India 74%, Nigeria 74%, Brazil 69%, Ethiopia 80%, Uganda 82%, Mozambique 76%, and the United Republic of Tanzania 85%. These values can be compared directly because they share the same year field.
| Country | Value | Observation year | Comparison note |
|---|---|---|---|
| South Africa | 77% | 2025 | Same-year subset |
| India | 74% | 2025 | Same-year subset |
| Nigeria | 74% | 2025 | Same-year subset |
| Brazil | 69% | 2025 | Same-year subset |
| Ethiopia | 80% | 2025 | Same-year subset |
| United Republic of Tanzania | 85% | 2025 | Just below the 86% population target |
| United Kingdom | 88% | 2024 | Excluded from 2025 ranking |
| Germany | 89% | 2021 | Older latest observation |
Some familiar high-income countries in the latest-observation table have older reference years. The United Kingdom and Australia are both 88% in 2024; France is 89% in 2023; Canada is 72% in 2022; and Germany is 89% in 2021. Those numbers remain useful as each country’s retained latest observation, but placing them in a 2025 league table would mix time with cross-country differences.
Twenty-nine latest observations are older than 2025
The year distribution is important: 94 records are from 2025, nine from 2024, seven from 2023, three from 2022, five from 2021, two from 2019, one from 2018, and two from 2017. “Latest available” therefore does not mean “measured in the same year.” The hatched countries on the map make this timing difference visible rather than hiding it.
For broad coverage, the latest-observation map uses all 123 records. For the numerical distribution, ranking and summary statistics, this article uses only 2025 records. Separating those two views avoids treating a 2017 or 2021 observation as if it were contemporary with a 2025 observation.
Gray countries are missing values, not zero viral suppression
The statistical table contains 123 countries and areas, while 116 of them connect directly to visible ISO-3 polygons in the low-resolution Natural Earth layer used for the map. Barbados, Comoros, Cabo Verde, Malta, Mauritius, Singapore, and Sao Tome and Principe are examples of small statistical units that may not appear as separate filled polygons at this scale even though their observations remain in the calculations.
Countries such as the United States, Republic of Korea, China and Japan do not have retained observations in this 123-row country table and therefore remain gray as well. Gray should never be interpreted as a measured value of 0%. No missing country value has been replaced with zero or estimated from neighboring countries.
Viral suppression answers a different question from HIV prevalence or incidence
HIV prevalence measures how common HIV is in a population. Incidence measures new infections over a period. Population-level viral suppression instead asks how many of the people already living with HIV have reached the downstream treatment outcome of suppressed virus. A country can simultaneously have high HIV prevalence and high viral suppression, because one describes epidemic size while the other describes treatment-cascade performance.
Suppression matters both for health and for prevention. WHO’s guidance on HIV viral suppression emphasizes the health benefits of effective ART and sustained suppression. At the same time, this country-level indicator should not be treated as an individual clinical test result or a direct ranking of health systems. It is a national programme outcome built from surveillance and estimation processes.
Data source and calculation method
The values come from the WHO Global Health Observatory indicator HIV_VIRALLOADSUPPRESSED. The country table retains one latest non-missing total observation per country or area. It contains 123 observations spanning 2017–2025. No discovery-source prose or third-party article text is used to derive the country values.
All same-year summary statistics in this article are calculated from the 94 observations dated 2025. The map uses all 123 latest observations and visually marks records older than 2025. Country polygons come from a low-resolution Natural Earth boundary layer, so very small islands and territories may be absent as separate map shapes even when their statistical observations are included.
For interpretation, the WHO SMART HIV indicators explain viral suppression in the treatment cascade, while the current HIV and AIDS fact sheet provides the latest global context. The strongest use of this country comparison is to identify large differences, timing gaps and distance from the population-level 86% cascade target—not to over-interpret one- or two-point differences as precise rankings of programme quality.
Frequently Asked Questions
Is this indicator the same as the third 95?
No. The third 95 measures viral suppression among people receiving ART. This indicator uses all people living with HIV as the denominator. If all three cascade steps reach 95%, population-level suppression is about 86%.
Is 66.0% the global HIV viral-suppression rate for 2025?
No. It is the simple unweighted mean across the 94 country observations actually dated 2025. A global estimate uses a different aggregation and weighting framework.
Does high viral suppression mean a country has low HIV prevalence?
No. Prevalence measures how common HIV is, while viral suppression measures a treatment-cascade outcome among people living with HIV. A country can have high prevalence and high viral suppression at the same time.
Do gray countries on the map have 0% viral suppression?
No. Gray indicates no retained observation in this country table or no separately visible polygon in the low-resolution boundary layer.
Related Articles
- Tanzania 2022 Demographic, Health and Malaria Survey guide
- Rural access to basic drinking-water services
- Access to clean fuels and technologies for cooking
Green Map creates custom-edited map images using open geographic data sources such as geoBoundaries, Natural Earth, OpenStreetMap, and government open data.
These maps are edited visual materials, not raw data files, and are provided for education, documents, presentations, and graphic reference.
